Meeting
2013 ASCO Annual Meeting
TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).
Authors
Christos Vaklavas
University of Alabama at Birmingham, Birmingham, AL
Christos Vaklavas , Vandana Gupta Abramson , Nancy U. Lin , Minetta C. Liu , Hope S. Rugo , Rita Nanda , Anna Maria Storniolo , Tiffany A. Traina , Yufeng Li , Sujata Patil , Daniel F. Hayes , Catherine H. Van Poznak , Julie R. Nangia , William Johnson Irvin Jr., Helen Krontiras , Jennifer F. De Los Santos , Paul Haluska , Antonio C. Wolff , Andres Forero-Torres
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
F101004001
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1052)
DOI
10.1200/jco.2013.31.15_suppl.1052
Abstract #
1052
Poster Bd #
20C
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
First Author: Evan Justin Walker
Poster
2020 ASCO Virtual Scientific Program
CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).
First Author: Sara M. Tolaney
Poster
2015 ASCO Annual Meeting
A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
First Author: Sara M. Tolaney